MGX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Metagenomi Therapeutics Inc (MGX) is not a strong buy at this moment for a beginner, long-term investor with $50,000-$100,000 available. The lack of positive catalysts, weak financial performance, and absence of strong trading signals suggest that holding off on purchasing this stock is a more prudent decision.
The technical indicators are neutral. The MACD is positive but contracting, RSI is in the neutral zone at 43.711, and moving averages are converging. The stock is trading near its S1 support level of 1.388, with limited upward momentum based on current indicators.
NULL identified. No recent news or significant insider activity to indicate a positive catalyst.
Hedge funds are selling heavily, with a 323.12% increase in selling over the last quarter. Financial performance shows a significant YoY revenue drop of -24.80%, and the company remains unprofitable.
In Q3 2025, revenue dropped by -24.80% YoY to $8,659,000. Net income improved slightly YoY but remains negative at -$20,393,000. EPS also improved marginally to -0.55. Gross margin remains at 100%, but the overall financials indicate weak growth trends.
No analyst rating or price target changes available.
